Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

Report Ocean“Weight Loss and Weight Management Diet Market“ report offers a comprehensive analysis of the product/service industry, spanning from 2025-2033. It delves into his ...

Promoted by nutrition pros and research, the DASH diet is at the top of the diet charts. Learn why this is a smart eating plan and how it could benefit more than just your blood pressure.

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

Micronutrient deficiency, whereby levels of vitamins and minerals essential for healthy bodily function are far too low, is ...

For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures ...

Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...